Antipsychotic Use Trends in Youth With Autism Spectrum Disorder and/or Intellectual Disability: A Meta-Analysis
- PMID: 27238064
- DOI: 10.1016/j.jaac.2016.03.012
Antipsychotic Use Trends in Youth With Autism Spectrum Disorder and/or Intellectual Disability: A Meta-Analysis
Abstract
Objective: Although irritability and aggression are relevant treatment targets in autism spectrum disorders (ASDs) and intellectual disability (ID) that may prompt antipsychotic use, antipsychotic prescribing patterns in such youth have not been systematically reviewed.
Method: We systematically searched PubMed/MEDLINE/PsycInfo until March 2015 for studies reporting data on the frequency of youth diagnosed with ASDs and/or ID among antipsychotic-treated youth, as well as antipsychotic use in youth with ASD/ID, conducting a meta-analysis and meta-regression analysis of potential moderators, including publication year, study time point, country, setting, sample size, age, sex, and race/ethnicity.
Results: A total of 39 studies were meta-analyzed (n = 365,449, age = 11.4 ± 6.2 years, males = 70.0% ± 10.0%). Among 27 studies (n = 273,139, age = 11.9 ± 8.0 years, males = 67.0% ± 12.9%) reporting on antipsychotic-treated youth, 9.5% (95% CI = 7.8%-11.5%) were diagnosed with ASD/ID. In 20 studies (n = 209,756) reporting data separately for ASD, 7.9% (95% CI = 6.2%-9.9%) had an ASD diagnosis. In 5 longitudinal studies, the proportion of antipsychotic-treated youth with ASD did not change significantly from 1996 to 2011 (6.7% to 5.8%, odds ratio = 0.9, 95% CI = 0.8-1.0, p =.17). However, later study time point moderated greater ASD/ID proportions (β = 0.12, p < .00001). In 13 studies (n = 96,688, age = 9.8 ± 1.2 years, males = 78.6% ± 2.0%) reporting on antipsychotic use in ASD samples, 17.5% (95% CI = 13.7%-22.1%) received antipsychotics. Again, later study time point moderated higher antipsychotic use among patients with ASD (β = 0.10, p = .004).
Conclusion: Almost 1 in 10 antipsychotic-treated youth were diagnosed with ASD and/or ID, and 1 in 6 youth with ASD received antipsychotics. Both proportions increased in later years; however, clinical reasons and outcomes of antipsychotic use in ASD/ID require further study.
Keywords: adolescent; antipsychotic; autism; child; intellectual disability.
Copyright © 2016 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Trends in Antipsychotic Prescribing in Medicaid-Eligible Youth.J Am Acad Child Adolesc Psychiatry. 2017 Jan;56(1):59-66. doi: 10.1016/j.jaac.2016.10.005. Epub 2016 Oct 24. J Am Acad Child Adolesc Psychiatry. 2017. PMID: 27993230
-
Treatment of Young People With Antipsychotic Medications in the United States.JAMA Psychiatry. 2015 Sep;72(9):867-74. doi: 10.1001/jamapsychiatry.2015.0500. JAMA Psychiatry. 2015. PMID: 26132724
-
Extent, Time Course, and Moderators of Antipsychotic Treatment in Youth With Mood Disorders: Results of a Meta-Analysis and Meta-Regression Analyses.J Clin Psychiatry. 2017 Mar;78(3):347-357. doi: 10.4088/JCP.15r10435. J Clin Psychiatry. 2017. PMID: 28068462
-
Pharmacogenomic Studies in Intellectual Disabilities and Autism Spectrum Disorder: A Systematic Review.Can J Psychiatry. 2021 Dec;66(12):1019-1041. doi: 10.1177/0706743720971950. Epub 2020 Nov 23. Can J Psychiatry. 2021. PMID: 33222504 Free PMC article.
-
Lurasidone for the treatment of irritability and anger in autism spectrum disorders.Expert Opin Investig Drugs. 2017 Aug;26(8):985-989. doi: 10.1080/13543784.2017.1353600. Epub 2017 Jul 24. Expert Opin Investig Drugs. 2017. PMID: 28685626 Review.
Cited by
-
Integrative Management of Metabolic Syndrome in Youth Prescribed Second-Generation Antipsychotics.Med Sci (Basel). 2020 Aug 17;8(3):34. doi: 10.3390/medsci8030034. Med Sci (Basel). 2020. PMID: 32824428 Free PMC article. Review.
-
Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder.J Autism Dev Disord. 2017 Jul;47(7):2290-2294. doi: 10.1007/s10803-017-3132-2. J Autism Dev Disord. 2017. PMID: 28447303
-
Impact of Antipsychotic Guidelines on Laboratory Monitoring in Children with Neurodevelopmental Disorders.J Child Adolesc Psychopharmacol. 2021 Feb;31(1):79-83. doi: 10.1089/cap.2020.0096. Epub 2020 Oct 14. J Child Adolesc Psychopharmacol. 2021. PMID: 33052712 Free PMC article.
-
Excess cardiometabolic risk in children and adolescents initiating antipsychotic treatment compared to young adults: results from a nationwide cohort study.World Psychiatry. 2025 Feb;24(1):103-112. doi: 10.1002/wps.21279. World Psychiatry. 2025. PMID: 39810688 Free PMC article.
-
Association of Focused Medication Review With Optimization of Psychotropic Drug Prescribing: A Systematic Review and Meta-analysis.JAMA Netw Open. 2018 Oct 5;1(6):e183750. doi: 10.1001/jamanetworkopen.2018.3750. JAMA Netw Open. 2018. PMID: 30646263 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical